Metropolitan Life Insurance Company (MetLife)’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,129
| Closed | -$11.1K | – | 2485 |
|
|
2023
Q1 | $11.1K | Sell |
1,129
-117
| -9% | -$2K | ﹤0.01% | 2120 |
|
|
2022
Q4 | $23.3K | Hold |
1,246
| – | – | ﹤0.01% | 1931 |
|
|
2022
Q3 | $25.8K | Buy |
1,246
+585
| +89% | +$15K | ﹤0.01% | 1887 |
|
|
2022
Q2 | $13.7K | Sell |
661
-458
| -41% | -$12.9K | ﹤0.01% | 2225 |
|
|
2022
Q1 | $48.2K | Sell |
1,119
-2,827
| -72% | -$127K | ﹤0.01% | 1620 |
|
|
2021
Q4 | $236K | Sell |
3,946
-13
| -0.3% | -$1.04K | ﹤0.01% | 1912 |
|
|
2021
Q3 | $340K | Sell |
3,959
-5,078
| -56% | -$510K | ﹤0.01% | 1687 |
|
|
2021
Q2 | $1.01M | Buy |
9,037
+4,865
| +117% | +$467K | 0.01% | 1483 |
|
|
2021
Q1 | $465K | Buy |
4,172
+301
| +8% | +$39.6K | 0.01% | 1470 |
|
|
2020
Q4 | $411K | Buy |
3,871
+97
| +3% | +$12.9K | 0.01% | 1487 |
|
|
2020
Q3 | $525K | Buy |
3,774
+132
| +4% | +$27.5K | 0.01% | 1188 |
|
|
2020
Q2 | $1.18M | Buy |
3,642
+1,145
| +46% | +$184K | 0.02% | 638 |
|
|
2020
Q1 | $223K | Sell |
2,497
-272
| -10% | -$16.8K | ﹤0.01% | 1532 |
|
|
2019
Q4 | $110K | Buy |
2,769
+2,143
| +342% | +$64.5K | ﹤0.01% | 2282 |
|
|
2019
Q3 | $15.4K | Sell |
626
-1,815
| -74% | -$55.2K | ﹤0.01% | 2559 |
|
|
2019
Q2 | $86.1K | Hold |
2,441
| – | – | ﹤0.01% | 2384 |
|
|
2019
Q1 | $109K | Buy |
2,441
+63
| +3% | +$3.17K | ﹤0.01% | 2276 |
|
|
2018
Q4 | $114K | Hold |
2,378
| – | – | ﹤0.01% | 2184 |
|
|
2018
Q3 | $159K | Hold |
2,378
| – | – | ﹤0.01% | 2166 |
|
|
2018
Q2 | $112K | Buy |
2,378
+278
| +13% | +$15.3K | ﹤0.01% | 2257 |
|
|
2018
Q1 | $119K | Buy |
2,100
+697
| +50% | +$37.7K | ﹤0.01% | 2202 |
|
|
2017
Q4 | $70K | Sell |
1,403
-2,975
| -68% | -$184K | ﹤0.01% | 2435 |
|
|
2017
Q3 | $333K | Buy |
4,378
+80
| +2% | +$5.95K | ﹤0.01% | 1966 |
|
|
2017
Q2 | $404K | Hold |
4,298
| – | – | ﹤0.01% | 1861 |
|
|
2017
Q1 | $341K | Buy |
4,298
+335
| +8% | +$26.7K | ﹤0.01% | 1921 |
|
|
2016
Q4 | $330K | Sell |
3,963
-351
| -8% | -$31.7K | ﹤0.01% | 2031 |
|
|
2016
Q3 | $482K | Sell |
4,314
-99
| -2% | -$10.9K | ﹤0.01% | 1728 |
|
|
2016
Q2 | $489K | Hold |
4,413
| – | – | ﹤0.01% | 1723 |
|
|
2016
Q1 | $461K | Hold |
4,413
| – | – | ﹤0.01% | 1622 |
|
|
2015
Q4 | $356K | Hold |
4,413
| – | – | ﹤0.01% | 1859 |
|
|
2015
Q3 | $306K | Sell |
4,413
-82
| -2% | -$7.14K | ﹤0.01% | 1966 |
|
|
2015
Q2 | $440K | Buy |
+4,495
| New | +$480K | ﹤0.01% | 1834 |
|
|
2015
Q1 | – | Sell |
-3,910
| Closed | -$431K | – | 2318 |
|
|
2014
Q4 | $431K | Buy |
3,910
+404
| +12% | +$49.4K | ﹤0.01% | 1863 |
|
|
2014
Q3 | $414K | Sell |
3,506
-1,102
| -24% | -$137K | ﹤0.01% | 1835 |
|
|
2014
Q2 | $598K | Buy |
+4,608
| New | +$544K | ﹤0.01% | 1706 |
|
Other funds holding INO
Metropolitan Life Insurance Company (MetLife)'s INO Position: Q2 2023 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 1,129 shares — an estimated $11.1K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in INO in Q2 2014 and held it in 35 quarters. The position peaked at $1.18M in Q2 2020. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 1,129 Inovio Pharmaceuticals shares in Q2 2023, an estimated $11.1K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Inovio Pharmaceuticals in Q2 2014 and held it in 35 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Inovio Pharmaceuticals position peaked at $1.18M in Q2 2020.
- 133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.